Why the study?
The study was conducted to determine the diagnostic value of the systolic tricuspid regurgitation velocity/pulmonary artery flow velocity time integral to predict tricuspid regurgitation pressure gradient compared with other cardiac indices, and to investigate a prognostic cutoff value.
Does the systolic tricuspid regurgitation velocity/pulmonary artery flow velocity time integral predict pulmonary hypertension severity and prognosis in dogs?
Does the systolic tricuspid regurgitation velocity/pulmonary artery flow velocity time integral predict pulmonary hypertension severity and prognosis in dogs?
The systolic tricuspid regurgitation velocity/pulmonary artery flow velocity time integral is a useful non-invasive echocardiographic index for evaluating pulmonary hypertension severity and prognosis in dogs.
This retrospective, echocardiographic study using 144 dogs with clear systolic tricuspid regurgitation on Doppler echocardiography was performed to determine the diagnostic value of the systolic tricuspid regurgitation velocity/pulmonary artery flow velocity time integral to predict the Doppler estimates of dogs with tricuspid regurgitation pressure gradient compared with other cardiac indices of pulmonary hypertension, and to investigate a cutoff value to select patients with a potentially poor outcome. The systolic tricuspid regurgitation velocity/pulmonary artery flow velocity time integral increased significantly as the severity of pulmonary hypertension increased and had a correlation coefficient that was analogous to those of other conventional cardiac indices. A cutoff value greater 1.65 provided the best-balanced sensitivity (84%) and specificity (80%) in determining patients with a poor prognosis. In conclusion, the systolic tricuspid regurgitation velocity/pulmonary artery flow velocity time integral is readily obtained using routine echocardiography and could provide a non-invasive, novel, and supplementary index for evaluating dogs with pulmonary hypertension as useful prognostic criteria, particularly in those with advanced pulmonary hypertension.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: